Moreover, the inhibition of SDF-1/CXCR4 signaling can potentiate the action of other immunotherapeutic agents by improving the infiltration of effector T cells into the tumor core, a region that is typically characterized by hypoxia and high levels of immunosuppressive cytokines. This evidence concerns the gene CXCL12 and neoplasm.